150 related articles for article (PubMed ID: 30624197)
1. Utility of Human Epidermal Growth Factor Receptor 2 (HER2) Retesting of Histologic Grade 3 Invasive Breast Carcinomas.
Gologorsky R; Cureton E; Shim V
Perm J; 2019; 23():18-088. PubMed ID: 30624197
[TBL] [Abstract][Full Text] [Related]
2. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
Rakha EA; Pigera M; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
Histopathology; 2016 Jul; 69(1):20-4. PubMed ID: 26542743
[TBL] [Abstract][Full Text] [Related]
4. Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer.
Munch-Petersen HD; Rasmussen BB; Balslev E
APMIS; 2014 Sep; 122(9):750-4. PubMed ID: 24372587
[TBL] [Abstract][Full Text] [Related]
5. Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors.
Petrau C; Clatot F; Cornic M; Berghian A; Veresezan L; Callonnec F; Baron M; Veyret C; Laberge S; Thery JC; Picquenot JM
Am J Clin Pathol; 2015 Oct; 144(4):555-62. PubMed ID: 26386076
[TBL] [Abstract][Full Text] [Related]
6. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
Asogan AB; Hong GS; Arni Prabhakaran SK
Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
[TBL] [Abstract][Full Text] [Related]
7. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
[TBL] [Abstract][Full Text] [Related]
8. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.
Dekker TJ; Smit VT; Hooijer GK; Van de Vijver MJ; Mesker WE; Tollenaar RA; Nortier JW; Kroep JR
Ann Oncol; 2013 Apr; 24(4):931-7. PubMed ID: 23211940
[TBL] [Abstract][Full Text] [Related]
9. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
[TBL] [Abstract][Full Text] [Related]
10. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management.
Striebel JM; Bhargava R; Horbinski C; Surti U; Dabbs DJ
Am J Clin Pathol; 2008 Mar; 129(3):383-90. PubMed ID: 18285260
[TBL] [Abstract][Full Text] [Related]
11. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
12. Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs.
VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
Am J Surg Pathol; 2015 Jul; 39(7):939-47. PubMed ID: 25871620
[TBL] [Abstract][Full Text] [Related]
13. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
15. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
[TBL] [Abstract][Full Text] [Related]
16. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features of unexpectedly HER2 positive breast carcinomas: An institutional experience.
LaBoy C; Siziopikou KP; Rosen L; Blanco LZ; Pincus JL
Pathol Res Pract; 2021 Jun; 222():153441. PubMed ID: 33857853
[TBL] [Abstract][Full Text] [Related]
18. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.
Tsuda H; Kurosumi M; Umemura S; Yamamoto S; Kobayashi T; Osamura RY
BMC Cancer; 2010 Oct; 10():534. PubMed ID: 20925963
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor.
Mueller-Holzner E; Fink V; Frede T; Marth C
Breast Cancer Res Treat; 2001 Sep; 69(1):13-9. PubMed ID: 11759824
[TBL] [Abstract][Full Text] [Related]
20. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Robertson S; Rönnlund C; de Boniface J; Hartman J
Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
